Amarin Corp Plcuk (AMRN) Change in Accured Expenses (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Change in Accured Expenses of -$14.8 million for Q1 2026, up 15.54% year-over-year from -$12.8 million in Q1 2025, and down 221.18% quarter-over-quarter from $12.2 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Change in Accured Expenses data on file, last reported at -$14.8 million in Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at -$14.8 million, up 15.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.2 million (up 128.9% YoY), and the FY2025 annual result was $14.5 million, up 118.85% from the prior year.
- Change in Accured Expenses eased to -$14.8 million in Q1 2026 per AMRN's latest filing, from $12.2 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $61.0 million in Q2 2022 and troughed at -$69.7 million in Q1 2022.
- A 5-year average of -$10.6 million and a median of -$14.8 million in 2026 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses tumbled 1175.14% in 2022, then surged 176.85% in 2025.
- A 5-year view of Change in Accured Expenses shows it stood at -$28.1 million in 2022, then soared by 73.09% to -$7.6 million in 2023, then sank by 186.16% to -$21.6 million in 2024, then soared by 156.59% to $12.2 million in 2025, then tumbled by 221.18% to -$14.8 million in 2026.
- Business Quant data shows AMRN's Change in Accured Expenses at -$14.8 million in Q1 2026, $12.2 million in Q4 2025, and -$3.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | -629.00 Mn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -1.59 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -75.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | -702.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -3.50 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | -14.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.82 Mn |
| Mar 31, 2026 | -14.82 Mn |
| Dec 31, 2025 | 12.23 Mn |
| Dec 31, 2025 | 12.23 Mn |
| Sep 30, 2025 | -3.71 Mn |
| Sep 30, 2025 | -3.71 Mn |
| Jun 30, 2025 | 23.54 Mn |
| Jun 30, 2025 | 23.54 Mn |
| Mar 31, 2025 | -17.54 Mn |
| Mar 31, 2025 | -17.54 Mn |
| Dec 31, 2024 | -21.61 Mn |
| Dec 31, 2024 | -21.61 Mn |
| Sep 30, 2024 | -28.99 Mn |
| Sep 30, 2024 | -28.99 Mn |
| Jun 30, 2024 | 8.50 Mn |
| Jun 30, 2024 | 8.50 Mn |
| Mar 31, 2024 | -34.90 Mn |
| Mar 31, 2024 | -34.90 Mn |
| Dec 31, 2023 | -7.55 Mn |
| Dec 31, 2023 | -7.55 Mn |